1. 1) Travis WD, et al: An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188: 733-748, 2013.
2. 2) Distler O, et al: Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 380: 2518-2528, 2019.
3. 3) Flaherty KR, et al: Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 381 (18): 1718-1727, 2019.
4. 4) Raghu G, et al: Diagnosis of idiopathic pulmonary fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 198: e44-68, 2018.
5. 5) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編: 特発性間質性肺炎 診断と治療の手引き (改訂第3版). 南江堂, 東京, 2016.